Behavioral Symptoms clinical trials

Explore recruiting behavioral symptoms clinical trials.

Recruiting behavioral symptoms studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Behavioral Symptoms trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms of Radiprodil in Patients with Tuberous Sclerosis Complex (TSC) or Focal Cortical Dysplasia (FCD) Type II.

Spain, Poland, Italy, Netherlands, Belgium

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Multicentric, Drug-Repositioning, Self Controlled Case Series (SCCS) Clinical Trial to Evaluate the Efficacy and Safety of Perampanel in Improving Behavioral Symptoms and Increasing the Quality of Life in Patients with White-Sutton syndrome (POGZ-Related Disorder)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

The efficacy of pipamperone and aripiprazole on behaviors that challenge in people with intellectual disabilities: A series of N-of-1 cross-over trials

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild to Moderate Alzheimer’s Disease (MINDSET 2)

Germany, Netherlands, Portugal, France, Spain, Poland +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Placebo-Controlled, Double-Blind Study of XPro™ in Patients with Early Alzheimer’s Disease with Biomarkers of Inflammation

Poland, France, Spain, Germany, Czechia, Slovakia

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild to Moderate Alzheimer’s Disease (MINDSET 1)

Germany, Croatia, Italy, Poland, Romania, Czechia +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Behavioral Symptoms trials by city

Behavioral Symptoms in Toronto Behavioral Symptoms in Vancouver Behavioral Symptoms in Montreal Behavioral Symptoms in Calgary Behavioral Symptoms in Edmonton Behavioral Symptoms in Ottawa Behavioral Symptoms in Winnipeg Behavioral Symptoms in Quebec City Behavioral Symptoms in Hamilton Behavioral Symptoms in Kitchener Behavioral Symptoms in London Behavioral Symptoms in Halifax Behavioral Symptoms in New York Behavioral Symptoms in Los Angeles Behavioral Symptoms in Chicago Behavioral Symptoms in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease